| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1161/01.CIR.97.14.1411 |
| P698 | PubMed publication ID | 9577953 |
| P2093 | author name string | Brown NJ | |
| Vaughan DE | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1411-1420 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Angiotensin-converting enzyme inhibitors | |
| P478 | volume | 97 |
| Q26764784 | 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension |
| Q92463069 | 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension |
| Q38311340 | A Review of Potential Marine-derived Hypotensive and Anti-obesity Peptides |
| Q35021448 | A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers |
| Q36125455 | A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors |
| Q34114542 | A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors |
| Q47598661 | ACE inhibition in secondary prevention: are the results controversial? |
| Q28218830 | ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors |
| Q35078456 | ACEI/ARB underused in patients with type 2 diabetes in Chinese population (CCMR-3B study). |
| Q46774246 | ANG II provokes acute trafficking of distal tubule Na+-Cl(-) cotransporter to apical membrane |
| Q42173727 | Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats |
| Q43558447 | Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy |
| Q44253929 | An unusual rearrangement of Zofenopril, a new ACE inhibitor drug: mass spectrometric and conformational studies |
| Q45235942 | Angiotensin I-converting enzyme inhibitory proteins and peptides from the rhizomes of Zingiberaceae plants |
| Q44174268 | Angiotensin II clamp prevents the second step in renal apical NHE3 internalization during acute hypertension |
| Q36160619 | Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes |
| Q79931107 | Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy |
| Q63684303 | Angiotensin-Converting Enzyme Inhibitor Use and Incident Frailty: A Longitudinal Cohort Study |
| Q42757834 | Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation |
| Q43546773 | Angiotensin-converting enzyme gene polymorphism in a cohort of coronary angiography patients |
| Q37451495 | Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease |
| Q36565040 | Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. |
| Q36670162 | Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging |
| Q39397039 | Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies |
| Q35925785 | Angiotensin-converting enzyme inhibitors in the therapy of renal diseases |
| Q35813311 | Antihypertensive effect of long-term oral administration of jellyfish (Rhopilema esculentum) collagen peptides on renovascular hypertension |
| Q33616414 | Antihypertensive properties of plant-based prebiotics |
| Q35868231 | Arresting cardiovascular disease progression. Early treatment may counteract high risk |
| Q53605460 | Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. |
| Q56607936 | Atrial fibrillation |
| Q35980401 | Augmenting beta receptors in the heart: short-term gains offset by long-term pains? |
| Q38004832 | Benefit of Monascus-fermented products for hypertension prevention: a review. |
| Q49021624 | Binding of ACE-inhibitors to in vitro and patient-derived amyloid-β fibril models. |
| Q24610066 | Bioactive peptides from muscle sources: meat and fish |
| Q44295787 | Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease |
| Q48124340 | Blood capillary rarefaction and lymphatic capillary neoangiogenesis are key contributors to renal allograft fibrosis in an ACE inhibition rat model. |
| Q78251152 | Bradykinin-induced preconditioning in patients undergoing coronary angioplasty |
| Q38709069 | Bradykinin/B2 receptor activation regulates renin in M-1 cells via protein kinase C and nitric oxide |
| Q44590151 | Captopril and enalaprilat decrease antioxidant defences in human endothelial cells and are unable to protect against apoptosis |
| Q37167178 | Cardiac oxidative stress and dysfunction by fine concentrated ambient particles (CAPs) are mediated by angiotensin-II |
| Q36307923 | Cardiac resynchronization--a heart failure perspective. |
| Q57293266 | Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? |
| Q36203442 | Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors |
| Q58702027 | Characterization and Antioxidant and Angiotensin I-Converting Enzyme (ACE)-Inhibitory Activities of Gelatin Hydrolysates Prepared from Extrusion-Pretreated Milkfish () Scale |
| Q39680591 | Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses |
| Q51029274 | Chronic enalapril treatment increases transient outward potassium current in cardiomyocytes isolated from right ventricle of spontaneously hypertensive rats. |
| Q80038982 | Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty |
| Q43823409 | Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. |
| Q35013807 | Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists |
| Q34742268 | Clinical pharmacology of antihypertensive drugs |
| Q36851259 | Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients |
| Q41860101 | Comparative Effect of Lisinopril and Fosinopril in Mitigating Learning and Memory Deficit in Scopolamine-Induced Amnesic Rats. |
| Q36585285 | Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? |
| Q53966050 | Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. |
| Q33417350 | Contaminated heparin and outcomes after cardiac surgery: a retrospective propensity-matched cohort study |
| Q90679340 | Coronavirus uses as binding site in humans angiotensin-converting enzyme 2 functional receptor that is involved in arterial blood pressure control and fibrotic response to damage and is a drug target in cardiovascular disease. Is this just a phyloge |
| Q53155611 | Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. |
| Q56927452 | Cough and ACE Inhibitors: The Truth Beyond Placebo |
| Q33867082 | Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials |
| Q38314732 | Critical insights into the beneficial and protective actions of the kallikrein-kinin system |
| Q27680712 | Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme |
| Q36522680 | Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction |
| Q30279093 | Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction |
| Q42905094 | Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2. |
| Q39905504 | Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. |
| Q28829292 | Discovery and characterization of smORF-encoded bioactive polypeptides |
| Q36108207 | Discovery of novel inhibitors for the treatment of glaucoma |
| Q44135007 | Diuretic response to acute hypertension is blunted during angiotensin II clamp |
| Q28085554 | Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension |
| Q90027099 | Drugs in Development for Acute Kidney Injury |
| Q35097098 | Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension |
| Q90568585 | Effect of Treatment with Peptide Extract from Beef Myofibrillar Protein on Oxidative Stress in the Brains of Spontaneously Hypertensive Rats |
| Q42126425 | Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model |
| Q24657798 | Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure |
| Q44392680 | Effect of foxtail millet protein hydrolysates on lowering blood pressure in spontaneously hypertensive rats |
| Q31383623 | Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. |
| Q33226444 | Effects of ACE inhibition on proximal tubule sodium transport |
| Q44131576 | Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression |
| Q33653074 | Effects of dairy on metabolic syndrome parameters: a review |
| Q44556776 | Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. |
| Q38306848 | Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease |
| Q73064446 | Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts |
| Q43628583 | Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction |
| Q44313582 | Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease |
| Q42504473 | Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo. |
| Q43282343 | Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study |
| Q53907599 | Efficacy and Safety of Quinapril 40mg Once Daily as Monotherapy for Patients with Poorly Controlled Hypertension : The EUREKA Study. |
| Q44648444 | Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure |
| Q38690145 | Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives |
| Q36956841 | Emerging trends in metalloprotein inhibition |
| Q33574874 | Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release |
| Q44776902 | Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism |
| Q35338096 | Epidemiology and management of antiretroviral-associated cardiovascular disease |
| Q35999545 | Eplerenone: a review of its use in essential hypertension |
| Q35825857 | Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man |
| Q51761248 | Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. |
| Q36402666 | Exploring an optimum intra/postoperative management strategy for acute hypertension in the cardiac surgery patient |
| Q34104343 | Exploring the influence of the protein environment on metal-binding pharmacophores |
| Q36702083 | Fixed-dose combination lercanidipine/enalapril |
| Q37524447 | Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema |
| Q92586755 | Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans |
| Q80758313 | Haemodynamic effects in healthy horses treated with an ACE-inhibitor (Ramipril) |
| Q80215353 | Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment |
| Q27340170 | Host kinin B1 receptor plays a protective role against melanoma progression |
| Q28709124 | Identification of homophenylalanine biosynthetic genes from the cyanobacterium Nostoc punctiforme PCC73102 and application to its microbial production by Escherichia coli |
| Q54074169 | Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. |
| Q36681017 | Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors |
| Q50940025 | In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5. |
| Q47222519 | Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy |
| Q35167293 | Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies. |
| Q24198115 | Interventions for protecting renal function in the perioperative period |
| Q35087015 | Intrarenal angiotensin II and hypertension |
| Q55334166 | Isolated Visceral Angioedema Induced by Angiotensin-Converting Enzyme Inhibitor. |
| Q40873689 | Isolation of an Angiotensin I-Converting Enzyme Inhibitory Protein with Antihypertensive Effect in Spontaneously Hypertensive Rats from the Edible Wild Mushroom Leucopaxillus tricolor |
| Q34569218 | Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors |
| Q35683744 | Local Augmented Angiotensinogen Secreted from Apoptotic Vascular Endothelial Cells Is a Vital Mediator of Vascular Remodelling |
| Q52923773 | Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. |
| Q89310287 | Long-term yogurt consumption and risk of incident hypertension in adults |
| Q33826882 | Management of heart failure in children |
| Q27678293 | Metalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active Site |
| Q37538078 | Milk products, dietary patterns and blood pressure management |
| Q35469704 | Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors |
| Q35178446 | Modulating atherosclerosis through inhibition or blockade of angiotensin |
| Q28176355 | Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure |
| Q45193072 | Monitoring the large-scale production of the antihypertensive peptides RYLGY and AYFYPEL by HPLC-MS. |
| Q34628672 | Myocardial remodelling: pharmacological targets |
| Q33825289 | Myocyte contractile dysfunction with hypertrophy and failure: relevance to cardiac surgery |
| Q33737152 | N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelates |
| Q73884918 | New antihypertensive peptides isolated from rapeseed |
| Q35172470 | New horizons for stroke prevention: PROGRESS and HOPE. |
| Q34028215 | New insights into the renin-angiotensin system and hypertensive renal disease |
| Q73019273 | Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro |
| Q47267550 | No association of angiotensin-converting enzyme inhibitor or angiotensin 2 receptor blocker intake with acute kidney injury in patients undergoing kidney biopsy |
| Q47099705 | Novel Therapies for Acute Kidney Injury |
| Q35038361 | Novel angiotensin I-converting enzyme inhibitory peptides derived from an edible mushroom, Pleurotus cystidiosus O.K. Miller identified by LC-MS/MS. |
| Q36619235 | Novel therapeutic approaches to preserve the right ventricle |
| Q46349125 | Nutritional and Functional Bioactivity Value of Selected Azorean Macroalgae: Ulva compressa, Ulva rigida, Gelidium microdon, and Pterocladiella capillacea |
| Q34444817 | Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level |
| Q36588669 | Optimal medical management of peripheral arterial disease |
| Q34026094 | Overview of the management of pediatric heart failure |
| Q37877722 | Perindopril for the treatment of hypertension. |
| Q34360688 | Peripartum Cardiomyopathy: Current Therapeutic Perspectives |
| Q37428854 | Peripheral artery disease: potential role of ACE-inhibitor therapy |
| Q35860284 | Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study |
| Q35086882 | Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? |
| Q41759096 | Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs |
| Q44446944 | Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats |
| Q38859478 | Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure |
| Q58745328 | Pharmacology of valsartan, an angiotensin II receptor antagonist |
| Q92443249 | Potential Beneficial Effects of Vitamin D in Coronary Artery Disease |
| Q33668233 | Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema |
| Q26866515 | Potential of RAS inhibition to improve metabolic bone disorders |
| Q43106907 | Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. |
| Q33650699 | Practical considerations of the pharmacology of angiotensin receptor blockers |
| Q57480827 | Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties |
| Q28077186 | Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm |
| Q46490150 | Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease |
| Q50227932 | QM/MM investigation of the catalytic mechanism of angiotensin-converting enzyme |
| Q34511006 | Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders |
| Q37038295 | Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis |
| Q43907953 | Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis |
| Q36631374 | Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage. |
| Q46360951 | Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events |
| Q38230938 | Recent Research in Antihypertensive Activity of Food Protein-derived Hydrolyzates and Peptides. |
| Q36646876 | Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses |
| Q34554367 | Regulation of intrarenal angiotensin II in hypertension |
| Q37632261 | Reinventing the ACE inhibitors: some old and new implications of ACE inhibition |
| Q34542200 | Role of bradykinin in preconditioning and protection of the ischaemic myocardium |
| Q28079603 | Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart |
| Q34434606 | Safety of ACE inhibitor therapies in patients with chronic kidney disease |
| Q37315397 | Secoisolariciresinol Diglucoside (SDG) Isolated from Flaxseed, an Alternative to ACE Inhibitors in the Treatment of Hypertension |
| Q34996538 | Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? |
| Q46601439 | Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril |
| Q57214519 | Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response |
| Q37482199 | Strategies for managing perioperative hypertension |
| Q73109994 | Tailored therapy using dobutamine and nitroglycerin in advanced heart failure |
| Q37371607 | Target-directed catalytic metallodrugs |
| Q36106851 | Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates |
| Q33852189 | The Consumption of Dairy Products Is Associated with Reduced Risks of Obesity and Metabolic Syndrome in Korean Women but not in Men |
| Q37738019 | The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point |
| Q34094354 | The past, present and future of renin-angiotensin aldosterone system inhibition |
| Q30664916 | The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data |
| Q36085761 | The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. |
| Q37519741 | The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril |
| Q38967178 | Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. |
| Q35748838 | Tissue-specific inactivation of murine M6P/IGF2R. |
| Q38234364 | Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension |
| Q33652543 | Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA |
| Q53842206 | Treating Hypertension to Prevent Cognitive Decline and Dementia: Re-Opening the Debate. |
| Q46635911 | Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction |
| Q36166429 | Type 2 diabetes mellitus: a cardiovascular perspective |
| Q36608474 | Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches |
| Q45018890 | Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery. |
| Q34530229 | What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. |
| Q81127538 | [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?] |
| Q79756893 | [Angiotensin converting enzyme (ACE, CD143) in the regular pulmonary vasculature] |
| Q81194778 | [Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease] |
Search more.